Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Case Reports
. 2021 Nov 29;10(1):e0878.
doi: 10.1002/rcr2.878. eCollection 2022 Jan.

Switching from omalizumab to mepolizumab therapy improved extra-pulmonary abdominal and cutaneous vasculitis symptoms in a patient with eosinophilic granulomatosis with polyangiitis

Yu-Hsuan Chen  1 , Ping-Hung Kuo  1
Affiliations
Case Reports

Switching from omalizumab to mepolizumab therapy improved extra-pulmonary abdominal and cutaneous vasculitis symptoms in a patient with eosinophilic granulomatosis with polyangiitis

Yu-Hsuan Chen et al. Respirol Case Rep. .

Abstract

Eosinophilic granulomatosis with polyangiitis (EGPA) is a systemic vasculitis of small-to-medium-sized vessels. Both eosinophilic infiltration and vasculitis are thought to contribute to multi-organ damage. Some biologics have been used to reduce the required dose of corticosteroids in EGPA, but no single agent can ensure a complete control of this disease. Here, we describe a patient with anti-neutrophil cytoplasmic antibodies-negative relapsing EGPA whose asthma control was improved by omalizumab, but she continued to develop flares of abdominal and cutaneous vasculitis symptoms. After switching to mepolizumab therapy, her blood hypereosinophilia and extra-pulmonary symptoms were significantly improved. Moreover, the dose of daily maintenance corticosteroid could be tapered off. The experience from our case suggests that biologics targeting interleukin-5 may be more effective than omalizumab in the management of extra-thoracic manifestations in EGPA.

Keywords: eosinophilic granulomatosis with polyangiitis; extra‐pulmonary; mepolizumab; omalizumab; switching.

PubMed Disclaimer

Conflict of interest statement

None declared.

Figures

FIGURE 1
FIGURE 1
Axial and coronal views of the chest computed tomography during flare‐up (A1–A3) and remission (B1–B3) of eosinophilic granulomatosis with polyangiitis
FIGURE 2
FIGURE 2
Time course of blood eosinophil counts, treatments and clinical parameters. *Month 0: Initial visit to our hospital. ACT, Asthma Control Test; BVAS, Birmingham Vasculitis Activity Score; PEFR, peak expiratory flow rate
See this image and copyright information in PMC

Similar articles

See all similar articles

References

    1. Jennette JC, Falk RJ, Bacon PA, Basu N, Cid MC, Ferrario F, et al. 2012 revised International Chapel Hill Consensus Conference Nomenclature of Vasculitides. Arthritis Rheum. 2013;65(1):1–11. - PubMed
    1. Masi AT, Hunder GG, Lie JT, Michel BA, Bloch DA, Arend WP, et al. The American College of Rheumatology 1990 criteria for the classification of Churg‐Strauss syndrome (allergic granulomatosis and angiitis). Arthritis Rheum. 1990;33(8):1094–100. - PubMed
    1. Lanham JG, Elkon KB, Pusey CD, Hughes GR. Systemic vasculitis with asthma and eosinophilia: a clinical approach to the Churg‐Strauss syndrome. Medicine (Baltimore). 1984;63(2):65–81. - PubMed
    1. Doubelt I, Cuthbertson D, Carette S, Chung SA, Forbess LJ, Khalidi NA, et al. Clinical manifestations and long‐term outcomes of eosinophilic granulomatosis with polyangiitis in North America. ACR Open Rheumatol. 2021;3(6):404–12. - PMC - PubMed
    1. Comarmond C, Pagnoux C, Khellaf M, Cordier JF, Hamidou M, Viallard JF, et al. Eosinophilic granulomatosis with polyangiitis (Churg‐Strauss): clinical characteristics and long‐term followup of the 383 patients enrolled in the French Vasculitis Study Group cohort. Arthritis Rheum. 2013;65(1):270–81. - PubMed

Publication types

LinkOut - more resources